Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 58, Issue 24, Pages 9421-9437Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b00326
Keywords
-
Categories
Funding
- Foundation Solidar-Immun (Lausanne, Switzerland)
Ask authors/readers for more resources
Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies. Many novel IDO1 inhibitor scaffolds have been described, and a few potent compounds have entered clinical trials. However, a significant number of the reported compounds contain problematic functional groups, suggesting that enzyme inhibition could be the result of undesirable side reactions instead of selective binding to IDO1 Here, we describe issues in the employed experimental protocols, review and classify reported IDO1 inhibitors, and suggest different approaches for confirming viable inhibitor scaffolds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available